Hampton Creek Press (print and distribution provided by Simon & Schuster) Announces Behind a Closed Door, the Latest Novel by Writer J.D. Barker
April 17, 2024 13:51 ET
|
Hampton Creek Press
The long-awaited thriller from New York Times bestselling author J.D. Barker is available for preorder now and will be released on May 13, 2024.
aTyr Pharma to Participate in April Investor Conferences
April 01, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Participate in April Investor Conferences
AT&T and TransUnion Launch the Industry’s First In-Network Branded Call Display with Logos
January 30, 2024 08:00 ET
|
TransUnion
CHICAGO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- AT&T and TransUnion (NYSE: TRU) are now offering outgoing calls for businesses that display a brand name and logo on the receiver’s phone – with two...
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
January 29, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.
Tecnoglass Tops the Forbes List of America’s Most Successful Small-Cap Companies
November 16, 2023 07:00 ET
|
Tecnoglass Inc.
Miami, FL, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Tecnoglass, Inc. (NYSE: TGLS) ("Tecnoglass" or the "Company"), a leading producer of high-end aluminum and vinyl windows and architectural glass for the...
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
November 13, 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its...
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
November 09, 2023 16:00 ET
|
aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated...
[Latest] Global RFID Smart Cabinets Market Size/Share Worth USD 1,595.5 Million by 2032 at a 10.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
November 06, 2023 15:00 ET
|
Custom Market Insights
Austin, TX, USA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “RFID Smart Cabinets Market Size, Trends and Insights By Component (RFID Tags,...
Moxies announces the reopening of its revitalized Langley location
October 06, 2023 09:00 ET
|
Moxies
LANGLEY, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- MOXIES is delighted to announce the re-opening of its refurbished location at 8828 - 201 Street, Langley Twp. Elevating the dining...
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
September 11, 2023 08:00 ET
|
aTyr Pharma, Inc.
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...